The FDA has approved a subcutaneous injection induction regimen of Tremfya (guselkumab) for adults with moderately to severely active ulcerative colitis, according to a recent news release.

Tremfya is now the first and only IL-23 inhibitor to offer both subcutaneous and intravenous (IV) induction options for the treatment of ulcerative colitis and Crohn’s disease. The FDA approved both subcutaneous and intravenous forms of Tremfya for the treatment of Crohn’s disease in March 2025 . The IV formulation of Tremfya was approved by the FDA in Sept. 2024.

Inflammatory bowel disease affects approximately 3 million Americans. Ulcerative colitis and Crohn’s disease are two of the most common inflammatory bowel diseases in the United States. Both are considered autoimmune diseases. Ulcerative

See Full Page